|
1
|
Rakha EA and Ellis IO:
Triple-negative/basal-like breast cancer: review. Pathology.
41:40–47. 2009. View Article : Google Scholar
|
|
2
|
Leone F, Perissinotto E, Cavalloni G, et
al: Expression of the c-ErbB-2/HER2 proto-oncogene in normal
hematopoietic cells. J Leukoc Biol. 74:593–601. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McInnes KJ, Andersson TC, Simonytė K,
Söderström I, Mattsson C, Seckl JR and Olsson T: Association of
11β-hydroxysteroid dehydrogenase type I expression and activity
with estrogen receptor β in adipose tissue from postmenopausal
women. Menopause. 19:1347–1352. 2012.
|
|
4
|
Regil-Hallmann RS, Ibarra-del-Río M and
Flores-Hernández L: Correlación citohistológica en el Instituto
Nacional de Cancerología en el año 2006. Patología. 46:309–314.
2008.(In Spanish).
|
|
5
|
Mittendorf EA, Wu Y, Scaltriti M, et al:
Loss of HER2 amplification following trastuzumab-based neoadjuvant
systemic therapy and survival outcomes. Clin Cancer Res.
15:7381–7388. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vu T and Claret FX: Trastuzumab: updated
mechanisms of action and resistance in breast cancer. Front Oncol.
2:622012.PubMed/NCBI
|
|
7
|
González-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22.
2007.PubMed/NCBI
|
|
8
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moreno-Sánchez R, Saavedra E,
Rodríguez-Enríquez S, Gallardo-Pérez JC, Quezada H and Westerhoff
HV: Metabolic control analysis indicates a change of strategy in
the treatment of cancer. Mitochondrion. 10:626–639. 2010.PubMed/NCBI
|
|
10
|
Rodríguez-Enríquez S, Pacheco-Velázquez
SC, Gallardo-Pérez JC, et al: Multi-biomarker pattern for tumor
identification and prognosis. J Cell Biochem. 112:2703–2715.
2011.PubMed/NCBI
|
|
11
|
Moreno-Sánchez R, Rodríguez-Enríquez S,
Marín-Hernández A and Saavedra E: Energy metabolism in tumor cells.
FEBS J. 274:1393–1418. 2007.
|
|
12
|
Moreno-Sánchez R, Rodríguez-Enríquez S,
Saavedra E, Marín-Hernández A and Gallardo-Pérez JC: The
bioenergetics of cancer: is glycolys the main ATP supplier in all
tumor cells? Biofactors. 35:209–225. 2009.PubMed/NCBI
|
|
13
|
Amon LM, Pitteri SJ, Li CI, et al:
Concordant release of glycolysis proteins into the plasma preceding
a diagnosis of ER+ breast cancer. Cancer Res.
72:1935–1942. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yeung SJ, Pan J and Lee MH: Roles of p53,
MYC and HIF-1 in regulating glycolysis: the seventh hallmark of
cancer. Cell Mol Life Sci. 65:3981–3999. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marín-Hernández A, Gallardo-Pérez JC,
Ralph SJ, Rodríguez-Enríquez S and Moreno-Sánchez R: HIF-1alpha
modulates energy metabolism in cancer cells by inducing
over-expression of specific glycolytic isoforms. Mini Rev Med Chem.
9:1084–1101. 2009.PubMed/NCBI
|
|
16
|
Gillies RJ and Gatenby RA: Adaptive
landscapes and emergent phenotypes: why do cancers have high
glycolysis? J Bioenerg Biomembr. 39:251–257. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xueguan L, Xiaoshen W, Yongsheng Z, Chaosu
H, Chunying S and Yan F: Hypoxia inducible factor-1 alpha and
vascular endothelial growth factor expression are associated with a
poor prognosis in patients with nasopharyngeal carcinoma receiving
radiotherapy with carbogen and nicotinamide. Clin Oncol.
20:606–612. 2008. View Article : Google Scholar
|
|
18
|
Brahimi-Horn M and Pouysségur J: HIF at a
glance. J Cell Sci. 122:1055–1057. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leon AC, Davis LL and Kraemer HC: The role
and interpretation of pilot studies in clinical research. J
Psychiatr Res. 45:626–629. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bartlett JE II, Kotrlik JW and Higginsm
CC: Organizational research: Determining appropriate sample size in
survey. Off Syst Res J. 19:43–50. 2001.
|
|
21
|
Ruíz-Godoy L, Meneses-García A, Suárez-Roa
L, Enriquez V, Lechuga-Rojas R and Reyes-Lira E: Organization of a
tumor bank: the experience of the National Cancer Institute of
Mexico. Pathobiology. 77:147–154. 2010.
|
|
22
|
Holland R, Peterse JL, Millis RR, Eusebi
V, Faverly D, van de Vijver MJ and Zafrani B: Ductal carcinoma in
situ: a proposal for a new classification. Semin Diagn Pathol.
11:167–180. 1994.PubMed/NCBI
|
|
23
|
Cheang MC, Chia SK, Voduc D, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar
|
|
24
|
Rodríguez-Enríquez S, Carreño-Fuentes L,
Gallardo-Pérez JC, et al: Oxidative phosphorylation is impaired by
prolonged hypoxia in breast and possibly in cervix carcinoma. Int J
Biochem Cell Biol. 42:1744–1751. 2010.PubMed/NCBI
|
|
25
|
Marín-Hernández A, Rodríguez-Enríquez S,
Vital-González PA, Flores-Rodríguez FL, Macías-Silva M,
Sosa-Garrocho M and Moreno-Sánchez R: Determining and understanding
the control of glycolysis in fast-growth tumor cells. Flux control
by an over-expressed but strongly product-inhibited hexokinase.
FEBS J. 273:1975–1988. 2006.PubMed/NCBI
|
|
26
|
Lilliefors HW: On the Kolmogorov-Smirnov
Test for normality with mean and variance unknown. J Am Statistical
Assoc. 62:399–402. 1967. View Article : Google Scholar
|
|
27
|
Young DA, Zerbe GO and Hay WW Jr:
Fieller’s theorem, Scheffé simultaneous confidence intervals, and
ratios of parameters of linear and nonlinear mixed-effects models.
Biometrics. 53:838–847. 1997.
|
|
28
|
Krauth J: The interpretation of
significance tests for independent and dependent samples. J
Neurosci Methods. 9:269–281. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Abba MC, Lacunza E, Butti M and Aldaz CM:
Breast cancer biomarker discovery in the functional genomic age: a
systematic review of 42 gene expression signatures. Biomark
Insights. 5:103–118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salazar EL, Calzada L and Pedron N:
Infiltrating ductal/lobular carcinoma: an evaluation of prognostic
factors in primary breast cancer. Arch AIDS Res. 10:73–82.
1996.PubMed/NCBI
|
|
31
|
Gown AM: Current issues in ER and HER2
testing by IHC in breast cancer. Mod Pathol. 21:S8–S15. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Carey LA, Perou CM, Livasy CA, et al:
Race, breast cancer subtypes, and survival in the Carolina Breast
Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mitas M, Mikhitarian K, Walters C, et al:
Quantitative real-time RT-PCR detection of breast cancer
micrometastasis using a multigene marker panel. Int J Cancer.
93:162–171. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu AM and Huang PH: Receptor tyrosine
kinase coactivation networks in cancer. Cancer Res. 70:3857–3860.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Al-Lazikani B, Banerji U and Workman P:
Combinatorial drug therapy for cancer in the post-genomic era. Nat
Biotechnol. 30:679–692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pérez-Sánchez VM, Vela-Chávez TA and
Mora-Tiscareño MA: Diagnóstico histopatológico y factores
pronósticos en cáncer infiltrante de glándula mamaria.
Cancerología. 3:7–17. 2008.(In Spanish).
|
|
37
|
Maughan KL, Lutterbie MA and Ham PS:
Treatment of breast cancer. Am Fam Physician. 81:1339–1346.
2010.PubMed/NCBI
|
|
38
|
Weigel MT and Dowsett M: Current and
emerging biomarkers in breast cancer: prognosis and prediction.
Endocr Relat Cancer. 17:R245–R262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lari S and Kuerer H: Biological markers in
DCIS and risk of breast recurrence: a systematic review. J Cancer.
2:232–261. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lindström LS, Karlsson E, Wilking UM, et
al: Clinically used breast cancer markers such as estrogen
receptor, progesterone receptor, and human epidermal growth factor
receptor 2 are unstable throughout tumor progression. J Clin Oncol.
30:2601–2608. 2012.
|
|
41
|
Porporato PE, Dhup S, Dadhich RK, Copetti
T and Sonveaux P: Anticancer targets in the glycolytic metabolism
of tumors: a comprehensive review. Front Pharmacol. 2:492011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Talks KL, Turley H, Gatter KC, Maxwell PH,
Pugh CW, Ratcliffe PJ and Harris AL: The expression and
distribution of the hypoxia-inducible factors HIF-1alpha and
HIF-2alpha in normal human tissues, cancers, and tumor-associated
macrophages. Am J Pathol. 157:411–421. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhong H, De Marzo AM, Laughner E, et al:
Overexpression of hypoxia-inducible factor 1alpha in common human
cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
44
|
Vleugel MM, Greijer AE, van der Wall E and
van Diest PJ: Mutation analysis of the HIF-1alpha oxygen-dependent
degradation domain in invasive breast cancer. Cancer Genet
Cytogenet. 163:168–172. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Balinsky D, Platz CE and Lewis JW: Isozyme
patterns of normal, benign, and malignant human breast tissues.
Cancer Res. 43:5895–5901. 1983.PubMed/NCBI
|
|
46
|
Lee WY, Huang SC, Hsu KF, Tzeng CC and
Shen WL: Roles for hypoxia-regulated genes during cervical
carcinogenesis: somatic evolution during the
hypoxia-glycolysis-acidosis sequence. Gynecol Oncol. 108:377–384.
2008. View Article : Google Scholar
|
|
47
|
Piruat JI and López-Barneo J: Oxygen
tension regulates mitochondrial DNA-encoded complex I gene
expression. J Biol Chem. 280:42676–42684. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rexer BN and Arteaga CL: Intrinsic and
acquired resistance to HER2-targeted therapies in HER2
gene-amplified breast cancer: mechanisms and clinical implications.
Crit Rev Oncog. 17:1–16. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Banerji S, Cibulskis K, Rangel-Escareno C,
et al: Sequence analysis of mutations and translocations across
breast cancer subtypes. Nature. 486:405–409. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rodríguez-Enríquez S, Marín-Hernández A,
Gallardo-Pérez JC, Carreño-Fuentes L and Moreno-Sánchez R:
Targeting of cancer energy metabolism. Mol Nutr Food Res. 53:29–48.
2009.
|
|
51
|
Rodríguez-Enríquez S, Hernández-Esquivel
L, Marín-Hernández A, Dong LF, Akporiaye ET, Neuzil J, Ralph SJ and
Moreno-Sánchez R: Molecular mechanism for the selective impairment
of cancer mitochondrial function by a mitochondrially targeted
vitamin E analogue. Biochim Biophys Acta. 1817:1597–1607.
2012.PubMed/NCBI
|
|
52
|
el Guerrab A, Zegrour R, Nemlin CC, et al:
Differential impact of EGFR-targeted therapies on hypoxia
responses: implications for treatment sensitivity in
triple-negative metastatic breast cancer. PLoS One.
6:e250802001.PubMed/NCBI
|
